However, for this cohort of patients with osteosarcoma (OS), we did not specifically design our panel to identify TP53 intron 1 rearrangements, as has recently been reported in OS [12], and more TP53 mutation might be missing due to the WES approach. The gene discussed is TP53; the disease is osteosarcoma.